序贯帕博利珠单抗与AVD方案在未经治疗霍奇金淋巴瘤中于任意PD-L1表达水平均高度有效
这项多中心2期研究者发起的试验评估序贯帕博利珠单抗后AVD方案治疗未经治疗的不利或晚期经典霍奇金淋巴瘤。30例患者先接受3周期帕博利珠单抗单药,后接受4至6周期AVD。中位随访33.1个月时无进展生存和总生存均保持100%,所有患者9p24.1存在基因组改变且PD-L1免疫组化阳性,单药缓解深度与9p24.1改变或PD-1通路H评分无关。
要点
- 序贯帕博利珠单抗后AVD方案在未经治疗经典霍奇金淋巴瘤中显示高度有效。
- 中位随访33.1个月时无进展生存和总生存均保持100%。
- 所有患者9p24.1存在基因组改变且PD-L1免疫组化阳性。
核心结论
- 序贯帕博利珠单抗和AVD方案在额外随访后仍高度有效。
- 在所有PD-L1水平观察到的高缓解率提示,即使低水平PD-L1表达也足以对未经治疗经典霍奇金淋巴瘤的PD-1阻断产生缓解。
- 一项国际2期试验(注册号NCT03226249)正在进行以确认本研究发现。
研究设计与样本
- 多中心、2期、研究者发起的试验。
- 30例未经治疗的不利或晚期经典霍奇金淋巴瘤患者接受3周期帕博利珠单抗单药,随后根据分期和肿瘤负荷接受4至6周期AVD化疗。
主要发现
- 在帕博利珠单抗单药治疗后,近三分之二患者达到PET定义的完全或近完全代谢缓解(CMR)。
- 在2周期AVD后,所有患者达到CMR,初次发表时100%患者存活且无复发。
- 中位随访33.1个月(范围26.0-43.0)时,无进展生存和总生存均保持100%。
- 所有患者9p24.1存在基因组改变且PD-L1免疫组化阳性。
- 单药帕博利珠单抗的缓解深度与9p24.1改变或PD-1通路H评分之间无关系。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In a multicenter, phase 2, investigator-initiated trial of sequential pembrolizumab and AVD (doxorubicin, vinblastine, and dacarbazine), nearly two-thirds of patients with untreated, unfavorable, or advanced-stage classic Hodgkin lymphoma (cHL) achieved positron emission tomography (PET)-defined, complete or near-complete metabolic responses (CMRs), following pembrolizumab monotherapy. Furthermore, all patients achieved CMR after 2 cycles of AVD, with 100% of patients alive and without relapse at initial publication. We now report long-term follow-up, including the 3-year overall survival (OS) and planned correlative analyses. Thirty patients received 3 cycles of single-agent pembrolizumab, followed by AVD chemotherapy for 4 to 6 cycles depending on the stage and bulk. PET/computed tomography scan was performed after pembrolizumab monotherapy, 2 cycles of AVD, and at the end of therapy. Baseline biopsy samples were analyzed for genomic alterations of chromosome 9p24.1 and programmed cell death protein 1 (PD-1) pathway markers. At a median follow-up of 33.1 months (range, 26.0-43.0), progression-free survival and OS remained 100%. All patients had genomic alterations in 9p24.1 and were positive for programmed death ligand 1 (PD-L1) by immunohistochemistry. There was no relationship between depth of response to single-agent pembrolizumab and 9p24.1 alterations or PD-1 pathway H-scores. After additional follow-up, sequential pembrolizumab and AVD remained highly effective. The high response rates observed at all PD-L1 levels suggest that even low levels of PD-L1 expression are sufficient for response to PD-1 blockade in untreated cHL. An international phase 2 trial (registered at www.clinicaltrials.gov as #NCT03226249) is ongoing to confirm our findings.
引用
- Allen PB, Lu X, Chen Q, et al. Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma. Blood Adv. 2023. PMID: 36083129. doi:10.1182/bloodadvances.2022008116
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。